

4P-Pharma appoints Patrice Denèfle as Chief Scientific Officer

Lille, France, 26 May 2020 – 4P-Pharma, a biotechnology company specialised in the sourcing and the development of early stage therapeutic molecules, announces the appointment of Patrice Denèfle, PhD, HDR, Adjunct Prof., as its Chief Scientific Officer (CSO).

“We are delighted to welcome Patrice to our team as Chief Scientific Officer”, said Revital Rattenbach, Founder and President of 4P-Pharma. “Patrice’s scientific talent, strong translational medicine background, and executive leadership positions in large pharmaceutical and biotechnology companies makes him ideally suited to accelerate the development of 4P004, our Disease Modifying Osteoarthritis Drug, towards the clinic by 2021. Patrice also brings his extensive experience in building innovative and successful drug development programs, and I look forward to work closely with him to push forward 4P-Pharma’s strong momentum.”

Dr. Denèfle brings over 35 years of experience in large pharmaceutical and biotechnology companies in France and USA. Before joining 4P-Pharma, Dr. Denèfle spent 5 years as Head and General Manager of the Roche Institute for Research and Translational Medicine with the aim to transform discoveries from fundamental research into applications for patients through close partnerships with the biomedical research community. Prior to this role, Dr. Denèfle held leadership roles such as Director of Functional Genomics Department at Sanofi Aventis and as VP of the Digital & Translational Sciences platform at Ipsen. He has also been CSO and Head of Translational R&D at Genethon, a non-for-profit biotech financed by the patient association AFM-Téléthon (French Muscular Dystrophy Association) fully dedicated to the design and development of gene therapy treatments for rare diseases.

“I am thrilled to join 4P-Pharma team as CSO, as the company has a very impressive record of innovative projects addressing key medical needs for patients with chronic diseases, especially 4P004, a promising disease modifier for Osteoarthritis, which is progressing towards the clinic”, said Patrice Denèfle. “I am looking forward to work with all the team of 4P-Pharma and its scientific and advisory board to support and boost the clinical development of 4P004 and bring my expertise to expand 4P-Pharma’s portfolio drug candidates.”

About 4P-Pharma

4P-Pharma is a French biotechnology company specialized in the sourcing and the development of early stage therapeutic molecules addressing unmet medical needs for human and animal health. 4P-Pharma's strategy aims to detect the most promising early-stage projects from partners (i.e. academic institutions, small biotechs and TTOs) and perform in-house technological due-diligence applying stringent criteria. 4P-Pharma gather all the relevant actors from the clinic, drug development, finance and business fields to move technologies through developmental decision, building bridges to bring innovations to clinical phases and closer to patients' bedside. Since the foundation of 4P-Pharma in 2014, more than 250 molecules have been pre-evaluated, a technological due diligence has been carried out on 12 of them, and 2 have been selected to be developed until the clinical stage. One of these drug candidates, 4P004, is currently developed for the treatment of Osteoarthritis.

Website: www.4p-pharma.com

LinkedIn: www.linkedin.com/company/4p-pharma

Twitter: @4P_Pharma



4P-Pharma press contact

Roselina Lam, Business Development & Licensing Manager

Phone: +33 7 49 16 02 27 – E-mail: roselina@4p-pharma.com